Tor-Einar Svae, Head of IBU Immunotherapy Octapharma Group

Our specialization in immunotherapy warrants the continuous improvement and development of therapeutic concepts in numerous medical areas. It is this long-term commitment of Octapharma to patients requiring immunoglobulin which makes a difference.

Immunotherapy Portfolio

High purity 5% IVIG with long-term documented efficacy and tolerability

 

High purity 10% IVIG with proven safety and tolerability at high infusion rates

 

High purity,  high concentration 16.5% SCIG with low viscosity and long-term documented tolerability 

Immunoglobulin containing Rh(D) antibodies obtained from immunized donors which prevents hemolytic disease of the newborn

 

About Octapharma : Immunotherapy

Octapharma's Immunotherapy Portfolio comprises high-purity human immunoglobulin products for treating various immune-mediated diseases and deficiencies.

 

These products form the lifeline to health and hope for countless patients and their families around the globe. They are amongst the most tolerable of their class and are market leaders in many countries.

This unique portfolio offers multiple advantages:

  • A common production process facilitating the switch between Octapharma immunoglobulin products for the patients without triggering tolerability issues
  • Different product concentrations and routes of administration

  • Broad range of filling sizes

  • Simplified supply management of products coming from one single partner

  • A trusted company exclusively dedicated to human plasma and protein therapies